Eriksson BI, Borris LC, Friedman RJ et al.; RECORD1 Study Group.
N Engl J Med 2008;358:2765–75.
This trial demonstrated that the novel oral, direct, selective Factor Xa inhibitor, rivaroxaban, is significantly more effective at preventing venous thromboembolism after total hip arthroplasty than enoxaparin, while having a similar safety profile.
In this randomized, double-blind, Phase III clinical trial – RECORD1 (Regulation of Coagulation in Orthopaedic Surgeryto Prevent Deep Venous Thrombosis and Pulmonary Embolism 1) – a new oral anticoagulant, rivaroxaban, was compared with enoxaparin (a low-molecular-weight heparin [LMWH]) for the prevention of venous thromboembolism (VTE) in patients undergoing total hip arthroplasty (THA). Rivaroxaban is a direct, sel